Latest: QIAGEN launches the new LIAISON LymeDetect Assay based on QuantiFERON in partnership...
Latest: Targeting protein-protein interactions (PPIs): Identifying PPI inhibitors for novel...
Latest: Waters and Genovis collaborate to develop efficient workflows for biopharmaceutical...
Latest: What the UK’s FSA wants to see on submissions for CBD product authorization
Latest: Promoting more sustainable mining practices with Malvern Panalytical’s water monitoring...
Latest: Win big with SelectScience by sharing your opinion on laboratory products!
Latest: ZEISS has introduced a new microscopy slide scanner
Meet the analytical balance punching well above its weight
Advance your drug discovery and development with improved drug screening, imaging, and...
Synthetic antibody offers ultra-high sensitivity for next wave of COVID-19 sensors
BUCHI optimizes safety and durability of industrial evaporation with new 50 L Rotavapor® R-250 Pro
How to measure immune cell killing of tumor cells effectively
Take your pick of 8 expert webinars this week
Increasing LC-MS accessibility for streamlined biotherapeutic analysis
The essential guide to ELISA automation
Using spatial phenotypic signatures to predict immunotherapy response
See the whole picture with the 7250 GC/Q-TOF
Protocols for use of SuperNova v428 conjugated antibodies in a variety of flow cytometry...
SuperNova v428: New bright polymer dye for flow cytometry applications
Microplate Readers
DNA/RNA Purification and Analysis
Pre-Clinical and Clinical Automation
Cell Counting Technology
Cell Analysis Microscopy Equipment
Multiplexing Technology
COVID-19 Research
Virtual Analytical Summit
SelectScience Virtual Summit...
11 May 21 - 12 May 21
SelectScience Webinar...
21 May 21 - 25 May 21
07 Jun 21 - 11 Jun 21
SelectScience Virtual...
22 Jun 21 - 23 Jun 21
SLAS Europe 2021
22 Jun 21 - 25 Jun 21
The following whitepaper offers seven approaches recommended by Covance to reduce common inflammation clinical study challenges. These proactive approaches are based on our experience carrying out clinical trials in this area, as well as an acknowledgement that the re-applicability of therapies to different Immune-Mediated Inflammatory Disorders (IMIDs) also enables operational improvements to the conduct of IMID clinical trials.
Download this Article
Covance Regulatory Services
Covance Clinical Development (Phase II-...
Covance Clinical Development (Phase I-I...
Advertisement